Ireland
--:--IST
Recruiting Not applicable

Gastric Insufflation Volume Using I-gel Versus Ambu AuraGain in Pediatric Patients Undergoing Elective Orthopedic Operations Under General Anesthesia

NCT06853756 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2023-08-01
Last updated
2025-03-03

Condition(s) studied

Gastric InsufflationI-gelAmbu AuraGainPediatricOrthopedic OperationsGeneral Anesthesia

Investigational drug(s) / intervention(s)

Ambu AuragainI-gel

Ambu Auragain: Ambu Auragain was inserted after induction.

I-gel: The I-gel device was inserted after induction.

Study summary

Our study aimed to compare the gastric insufflation volume between Ambu AuraGain and i-gel and its relationship with the oropharyngeal sealing pressure and the incidence of postoperative complications in generally anesthetized controlled-ventilated pediatric patients undergoing elective orthopedic operations.

Eligibility

Sex
ALL
Min age
2 Years
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria: * Aged from 2 to 12 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status I and II. * Scheduled for elective orthopedic operations in a supine position under general anesthesia. Exclusion Criteria: * Patients with a known history of gastro-oesophageal reflux disorders. * Full Stomach. * Anticipated difficult mask ventilation or intubation. * Body mass index "BMI" exceeding 20% of the ideal. * A history of chest problems. * History of the gastrointestinal tract or thoracic surgeries.

Primary outcome measure(s)

  • Gastric antrum cross-sectional area (CSA) — At the end of surgery before supraglottic airway devices removal (5 min)
    Gastric antrum cross-sectional area (CSA) was measured before induction of general anesthesia, before supraglottic airway devices (SAD) insertion, after Ryle's tube insertion, and at the end of surgery before SAD removal.

Trial sites (1)

FacilityCityRegionStatus
Tanta University Tanta El-Gharbia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06853756 on ClinicalTrials.gov ↗ ← All trials in Egypt